HALIFAX, Jan. 21 /CNW/ - ImmunoVaccine Technologies Inc. (IVT), a
clinical stage vaccine development company, will receive $3 Million from the
Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation
Fund (AIF). This funding will enable IVT to undertake a $6 million project to
develop new potent immune enhancement systems.
"Having ACOA recognize the market potential of our innovative vaccine
platform is a tremendous boost," commented Brian Lowe, Vice President of IVT.
"This funding will enable us, over the next three years, to create novel
vaccines for the treatment of cancer and infectious diseases.
This funding announcement is the maximum grant awarded to a private
company under Round V of the AIF. The funds will further IVT's research
collaborations and commercialization opportunities with pharmaceutical
Atlantic Innovation Fund investments were announced earlier today by The
Honourable Peter MacKay, Minister of National Defence and Minister of the
Atlantic Canada Opportunities Agency. The Atlantic Innovation Fund is designed
to increase leading edge research and development (R&D) in Atlantic Canadian
research facilities, leading to the launch of new ideas, products, processes
About the VacciMax(R) Platform
ImmunoVaccine Technologies Inc. (IVT) has developed a breakthrough
vaccine-enhancement technology - the VacciMax(R) platform. It is comprised of
a mixture of liposomes and adjuvants. The VacciMax(R) platform is able to
stimulate an earlier, more powerful, long lasting immune response that could
provide a new way to treat a wide range of diseases.
The opportunities for market applications and medical benefits for the
VacciMax(R) platform are broad, and include prostate, breast, cervical,
ovarian, colon and lung cancer treatments, as well as vaccines for pandemic
influenza and other infectious diseases. www.immunovaccine.com
For further information:
For further information: Brian Lowe, Vice President IVT, (902) 492-1819,
email@example.com; Jennifer Ayotte, Communications, (902) 209-4704,